Please assess the completion status of the following clinical trial:

Trial Title: A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 12 years old;~* Resident of Toledo city;~* Seeking care in the public healthcare system with symptoms suggestive of COVID-19 defined as follows: 1) ARI symptoms (nasal congestion, rhinorrhea, anosmia, sore throat, hoarseness, new or increased-from-baseline cough, sputum production, dyspnea, wheezing, myalgia) OR 2) Admitting diagnosis suggestive of ARI (pneumonia, upper respiratory infection, bronchitis, influenza, cough, asthma, viral respiratory illness, respiratory distress, AND/OR respiratory failure).~* Nasal sample for SARS-CoV-2 diagnosis obtained as standard of care.~Exclusion Criteria:~* SARS-CoV-2-directed antiviral treatment within the past 30 days;~* COVID-19 monoclonal antibody therapy within the past 90 days;~* COVID-19 convalescent serum therapy within the past 90 days;~* Lack of consent to participate.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Fully vaccinated with BNT162b2 COVID-19 vaccine (Type: None): Defined as 2 doses of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥7 days between receipt of the 2nd dose and acute respiratory illness (ARI) symptom onset. This group will serve as the 'exposed' group evaluated in the primary objective.
- Ever vaccinated with BNT162b2 COVID-19 vaccine (Type: None): defined as ≥1 dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
- Partially vaccinated with BNT162b2 COVID-19 vaccine (Type: None): Defined as 1 dose (only) of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
- Fully vaccinated with other available COVID-19 vaccines (Type: None): Defined as fully vaccinated with available COVID-19 vaccines other than the BNT162b2 according to the manufacturer recommendations.
- Never vaccinated (Type: None): Defined as never received any COVID-19 vaccine. This group will serve as the reference exposure group (i.e., 'unexposed' group) in all vaccine effectiveness analyses.
- Fully vaccinated plus booster dose of BNT162b2 COVID-19 vaccine (Type: None): Defined as fully vaccinated with available COVID-19 vaccines according to the manufacturer recommendations plus booster dose of BNT162b2 COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.

Based on this trial design, predict the completion outcome and termination type (if applicable).